Ucello Therapeutics Company
Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20.
Technology:
CAR-T
Industry:
Private
Headquarters:
Chengdu, Sichuan, China
Founded Date:
2020-12-01
Funding Status:
Early Stage Venture
Investors Number:
5
Total Funding:
25000000
Estimated Revenue:
$10M to $50M
Last Funding Date:
2022-02-10
Last Funding Type:
Series A
Register and Claim Ownership